Your browser doesn't support javascript.
loading
Impact of bone marrow involvement on early positron emission tomography response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma.
Kreissl, Stefanie; Voltin, Conrad-Amadeus; Kaul, Helen; Bühnen, Ina; Mettler, Jasmin; Pabst, Thomas; Eichenauer, Dennis A; Fuchs, Michael; Diehl, Volker; Dietlein, Markus; Engert, Andreas; Borchmann, Peter; Kobe, Carsten.
Afiliação
  • Kreissl S; First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Centre for Integrated Oncology Aachen - Bonn - Cologne - Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Voltin CA; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Kaul H; First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Centre for Integrated Oncology Aachen - Bonn - Cologne - Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Bühnen I; First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Centre for Integrated Oncology Aachen - Bonn - Cologne - Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Mettler J; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Pabst T; Department of Medical Oncology, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Eichenauer DA; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland.
  • Fuchs M; First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Centre for Integrated Oncology Aachen - Bonn - Cologne - Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Diehl V; First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Centre for Integrated Oncology Aachen - Bonn - Cologne - Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Dietlein M; First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Centre for Integrated Oncology Aachen - Bonn - Cologne - Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Engert A; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Borchmann P; First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Centre for Integrated Oncology Aachen - Bonn - Cologne - Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Kobe C; First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Centre for Integrated Oncology Aachen - Bonn - Cologne - Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Br J Haematol ; 197(1): e5-e8, 2022 04.
Article em En | MEDLINE | ID: mdl-34929056

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Hodgkin Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Hodgkin Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article